XXII in the news

Damien Mulhem talked about XXII's flagship AI product Core on BFM Business's Tech & Co show.

Damien Mulhem, cofounder of XXII, presented their flagship AI product Core on a BFM Business tech podcast.

22nd Century secured $25M through stock sales to expand its reduced nicotine tobacco products amid improved financials but faces negative analyst outlook due to financial challenges.

22nd Century Group secured $9.5M insurance proceeds from a past incident, enabling a strategic focus on expanding its FDA-approved reduced-nicotine cigarette line.

22nd Century Group's stock jumped 39% after a $9.5 million insurance settlement boosts cash for growth, focusing on low-nicotine VLN tobacco products compliant with FDA standards.

22nd Century Group backs FDA's plan to cut nicotine in cigarettes, promoting their low-nicotine technology to reduce smoking-related deaths.

Premarket trading shows notable price swings in stocks like XXII, signaling potential trading opportunities before the market opens.

Premarket trading highlights notable price swings in stocks like XXII, signaling potential momentum for the day.

22nd Century Group eliminated over $20 million in debt and plans to expand production of its FDA-approved very low nicotine cigarettes by late 2025.

22nd Century Group is strategically positioned to capitalize on FDA nicotine reduction rules with its compliant VLN® cigarettes, aiming for EBITDA breakeven by 2026 amid strong market growth potential.

22nd Century Group expands distribution and product line of its FDA-authorized reduced nicotine tobacco products amid upcoming FDA nicotine content regulations.

22nd Century Group is transitioning to higher-margin low nicotine tobacco products aligned with FDA mandates, aiming for profitability by early 2026 despite recent losses and restructuring.

22nd Century Group will present at an investor conference about its VLN® low-nicotine cigarettes designed to help smokers reduce nicotine intake.

22nd Century Group will announce its Q2 2025 earnings on August 14, with a webcast led by its CEO and CFO discussing results and outlook.

The American Academy of Family Physicians supports the FDA's proposed nicotine reduction in cigarettes, with 22nd Century Group's VLN® products being the only FDA-approved compliant reduced nicotine cigarettes.

22nd Century Group expanded state approvals to boost sales of reduced nicotine cigarettes, improved financials in Q1 2025, but faces regulatory and market challenges.

22nd Century expanded state approvals to sell its low-nicotine VLN® cigarettes in 41 states ahead of the FDA mandate deadline.

22nd Century Group's FDA-authorized VLN® cigarettes reduce nicotine by 95%, helping smokers quit, with renewal due in 2026 and product expansion underway.

22nd Century Group is advancing its low nicotine cigarette line with a new 100mm product, showing revenue growth and improved financials despite regulatory and market challenges.